Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 12 Aug 2023 Results of planned exploratory analysis from NCT03303079 and NCT03303092 evaluating quality of life , published in the Headache
- 29 Jul 2021 Results assessing efficacy and safety of two dosing regimens of fremanezumab in Japanese and Korean patients with episodic migraine published in the Headache
- 24 Jun 2021 According to a Otsuka Pharmaceutical media release, the company received manufacturing and marketing approval from Ministry of Health, Labour and Welfare (MHLW) in Japan for AJOVY [Fremanezumab] Subcutaneous Injection 225 mg Syringe for the indication of preventive treatment of migraine in adult patients.